2021
The efficacy of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) on bone oligometastatic hormone-sensitive prostate cancer: A post hoc analysis of ARCHES.
Armstrong A, Iguchi T, Azad A, Villers A, Alekseev B, Petrylak D, Szmulewitz R, Alcaraz A, Shore N, Holzbeierlein J, Gomez-Veiga F, Rosbrook B, Zohren F, Haas G, Gourgioti G, El-Chaar N, Stenzl A. The efficacy of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) on bone oligometastatic hormone-sensitive prostate cancer: A post hoc analysis of ARCHES. Journal Of Clinical Oncology 2021, 39: 5071-5071. DOI: 10.1200/jco.2021.39.15_suppl.5071.Peer-Reviewed Original ResearchMetastatic hormone-sensitive prostate cancerAndrogen deprivation therapyEfficacy of enzalutamideHormone-sensitive prostate cancerBone metastasesTreatment armsProstate cancerOligometastatic hormone-sensitive prostate cancerPrior docetaxel chemotherapySecondary clinical outcomesDeprivation therapyEfficacy outcomesRadiographic progressionSecondary endpointsBaseline characteristicsDisease volumeDocetaxel chemotherapyMetastatic burdenPolymetastatic diseaseArch studyClinical outcomesCentral reviewClinical benefitSafety profilePlacebo
2020
Efficacy of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) by pattern of metastatic spread: ARCHES post hoc analyses.
Shore N, Armstrong A, Szmulewitz R, Petrylak D, Holzbeierlein J, Villers A, Azad A, Alcaraz A, Alekseev B, Iguchi T, Gomez-Veiga F, Rosbrook B, Lee H, Haas G, Stenzl A. Efficacy of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) by pattern of metastatic spread: ARCHES post hoc analyses. Journal Of Clinical Oncology 2020, 38: 5547-5547. DOI: 10.1200/jco.2020.38.15_suppl.5547.Peer-Reviewed Original ResearchRadiographic progression-free survivalEfficacy of enzalutamideAndrogen deprivation therapyMetastatic hormone-sensitive prostate cancerSymptomatic skeletal eventsSoft tissue metastasesMetastatic spreadVisceral metastasesSecondary endpointsBone metastasesFirst symptomatic skeletal eventHormone-sensitive prostate cancerProstate-specific antigen progressionLarge patient subgroupPrior docetaxel treatmentProgression-free survivalSecondary endpoint measuresGreater relative efficacyNew antineoplastic therapiesM0 patientsDeprivation therapyPrimary endpointSkeletal eventsCastration resistanceDisease volume
2014
A randomized open-label phase 2a study evaluating the efficacy and safety of radium-223 dichloride (Ra-223) in combination with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC) and bone metastases.
Petrylak D, Rosenberg J, Garosi V, Siegel J, Goldin J. A randomized open-label phase 2a study evaluating the efficacy and safety of radium-223 dichloride (Ra-223) in combination with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC) and bone metastases. Journal Of Clinical Oncology 2014, 32: tps5103-tps5103. DOI: 10.1200/jco.2014.32.15_suppl.tps5103.Peer-Reviewed Original Research
2007
Risk Factors for the Development of Bone Metastases in Prostate Cancer
Petrylak D. Risk Factors for the Development of Bone Metastases in Prostate Cancer. European Urology Open Science 2007, 6: 677-682. DOI: 10.1016/j.eursup.2007.03.005.Peer-Reviewed Original ResearchAndrogen deprivation therapyBone metastasesEarly prostate cancerProstate cancerRisk factorsEarly identificationDisease courseBone lossHigher baseline PSA levelsProstate-specific antigen levelChronic bone painHigh PSA velocityBaseline PSA levelsSpinal cord compressionMajority of patientsAdvanced prostate cancerBone health issuesBone health maintenanceBone mineral densityBone painCord compressionPalliative radiotherapyPSA velocitySkeletal complicationsPathologic fracture
2006
A phase I open-label, dose escalation study to determine the maximum tolerated dose and to evaluate the safety profile of lenalidomide with every three week docetaxel in subjects with androgen independent prostate cancer
Moss R, Shelton G, Melia J, Mohile S, Petrylak D. A phase I open-label, dose escalation study to determine the maximum tolerated dose and to evaluate the safety profile of lenalidomide with every three week docetaxel in subjects with androgen independent prostate cancer. Journal Of Clinical Oncology 2006, 24: 14618-14618. DOI: 10.1200/jco.2006.24.18_suppl.14618.Peer-Reviewed Original ResearchAndrogen-independent prostate cancerIndependent prostate cancerMeasurable diseaseProstate cancerSerum prostate-specific antigen levelProstate-specific antigen levelDose escalation schedulePrior chemotherapy regimensEvidence of progressionFurther dose escalationPhase I trialSpecific antigen levelsEfficacy of docetaxelDerivative of thalidomideAntiandrogen withdrawalL1 patientsPalliative RTPo bidStable diseaseChemotherapy regimensMedian PSARECIST criteriaEscalation studySerum PSABone metastasesClinical benefit of atrasentan for men with metastatic hormone-refractory prostate cancer metastatic to bone
Sleep D, Nelson J, Petrylak D, Isaacson J, Carducci M. Clinical benefit of atrasentan for men with metastatic hormone-refractory prostate cancer metastatic to bone. Journal Of Clinical Oncology 2006, 24: 4630-4630. DOI: 10.1200/jco.2006.24.18_suppl.4630.Peer-Reviewed Original ResearchHormone-refractory prostate cancerDisease progressionHRPC patientsBone metastasesProstate cancer metastaticKaplan-Meier methodDelays disease progressionEffects of endothelinDisease progression eventsCox proportional hazardsProgression of morbidityBone painCancer metastaticRadiographic progressionProlong survivalClinical benefitClinical progressionSelective endothelinClinical eventsReceptor antagonistMultinational trialProstate cancerClinical meansAtrasentanNew therapies